A compilation of scans of eight Peter Mac patients, created by Professor Michael Hofman and his research team, has been declared “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
The award was announced in Philadelphia in the US overnight.
The image - which demonstrates the dramatic before and after effect of LuPSMA therapy in men with advanced prostate cancer - was selected from more than 2,200 entries considered by the SNMMI.
“These images tell a story about exceptional responses observed in patients who had progressed after standard therapies. They match striking improvements in patient quality of life,” Prof Hofman said in response to the award.
“With further research, we look forward to seeing nuclear medicine evolve as a key specialty and standard-of-care in cancer management.”
Every year the SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging.
“This study by Michael Hofman and colleagues clearly shows the benefit to men with castrate-resistant prostate cancer treated with a beta emitter targeting PSMA when their tumors expressed PSMA,” chair of the SNMMI Scientific Program Committee Umar Mahmood said.
“It is gratifying to see the benefit of the approach both rigorously and objectively demonstrated in this trial, in terms of improvement in disease burden and improvement in the pain severity the men suffered.”
The image was generated as part of a Peter Mac-sponsored Phase II, single-arm study of LuPSMA the results of which were published by Lancet Oncology in May.